Lactobacillus Johnsonii Supplementation in Adults With T1D
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
While genetics demonstrated a major risk factor for the development of type 1 diabetes (T1D),
microbiota dysbiosis has been suggested as an elicitor in immunological tolerance and of beta
cell autoimmunity. The probiotic Lactobacillus johnsonii N6.2 may prevent or restore the gut
flora and show systemic impacts and adaptive immunity in the T1D population thereby
preserving beta cell function.
Phase:
Phase 2
Details
Lead Sponsor:
University of Florida
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)